AbbVie (ABBV) announced positive topline results from the Phase 3 CERVINO study evaluating etentamig in patients with triple-class exposed RRMM; study met its dual primary endpoints

The meaningful distinction in this space is between agents entering an already crowded class and those that genuinely extend it; BCMA-directed bispecifics now compete in a field that includes approved competitors, so the comparison against the existing standard of care, rather than the mere statistical hit, is what determines commercial weight. For a large-cap diversified pharma, single-asset oncology data of this kind has historically moved the shares modestly, with the bigger read-through reserved for pipeline-concentrated small caps, though a clean dual-endpoint win adds a degree of de-risking to the late-stage portfolio. The follow-ons are the full dataset presentation, the regulatory filing timeline, and any update on the safety profile, since cytokine release and infection rates have been the differentiators across the bispecific class. AbbVie's track record of advancing myeloma assets through this class is established, and the reaction tends to settle once the congress abstract lands.